Cat. No.: HY-N2322

Khasianine

3 Cited Publications

Avis client

Based on 3 publication(s) in Google Scholar

Khasianine is a steroidal glycoalkaloid. Khasianine alleviates psoriasis-like skin inflammation by inhibiting the TNF-α/NF-κB axis. Khasianine can downregulate the RhoA pathway and exhibits potential antimetastatic activity. Khasianine upregulates the expression of TNFR I and TNFR II without inducing apoptotic effects. Khasianine can be used in studies related to psoriasis, pancreatic ductal adenocarcinoma, and liver cancer.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.11%
CAS No.: 32449-98-2
Formule: C₃₉H₆₃NO₁₁
Masse moléculaire:721.92

Stockage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Khasianine Chemical Structure

CAS No.: 32449-98-2

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

IC50: antitumor activity^[1]

Voir tous les produits spécifiques à Isoform TNF Receptor :

Voir tous les produits spécifiques à Isoform NF-κB :

Voir tous les produits spécifiques à Isoform ROCK :

Cellular Effect

Cell Line	Type	Value	Description	References
PLC-PRF-5	ED₅₀	8.6 μg/mL Compound: khasianine	Cytotoxicity against human PLC/PRF/5 cells by microassay Cytotoxicity against human PLC/PRF/5 cells by microassay	[PMID: 2380724]

In Vitro

Khasianine (3.2-50 nM; 24 h) dose-dependently inhibits TNF-α-induced phosphorylation of NF-κB p65 at the Ser536 site in HaCaT cells without altering the level of total NF-κB p65^[1].
Khasianine (3.2-50 nM; 24 h) dose-dependently inhibits TNF-α-induced IL-17A and IL-33 protein expression in HaCaT cells^[1].
Khasianine (50 nM) blocks TNF-α-induced nuclear translocation of NF-κB p65 in HaCaT cells^[1].
Khasianine (50 nM) displaces NF-κB p65 from the promoter regions of IL-17A and IL-33, thereby inhibiting TNF-α-induced transactivation of these cytokines in HaCaT cells^[1].
Khasianine (3.2-12.5 nM) inhibits TNF-α-induced IL-17A mRNA expression in HaCaT cells in a dose-dependent manner, and significantly reduces TNF-α-induced IL-33 mRNA expression in these cells at a concentration of 12.5 nM^[1].
Khasianine (50-200 μM; 6 days) shows no obvious cytotoxicity against HaCaT cells at concentrations up to 200 μM during the 6-day incubation period^[1].
Khasianine (30-60 μg/mL) does not induce apoptotic cell death (characterized by a sub-G₁ peak) in human hepatocellular carcinoma Hep3B cells even at concentrations as high as 60 μg/mL^[3].
Khasianine (30-100 μg/mL; 48 h) inhibits the proliferation of human Suit2-007 cells and rat ASML pancreatic cancer cells, with IC₅₀ values of 50 μg/mL and 54 μg/mL, respectively^[2].
Khasianine (up to 20 μg/mL; 16 h) exhibits extremely low cytotoxicity against human hepatocellular carcinoma Hep3B cells, with an IC₅₀ greater than 20 μg/mL^[3].
Khasianine (50 μg/mL; 48 h) regulates the mRNA expression of glucose-sensitive LSBP in human Suit2-007 pancreatic cancer cells, with the most significant downregulation observed in lactose-sensitive LSBP, and downregulates the Sirtuin, RhoGTPase and RhoA signaling pathways^[2].
Khasianine (50 μg/mL; 48 h) regulates the protein expression of glucose-sensitive LSBP in human Suit2-007 pancreatic cancer cells, with the most significant down-regulation observed in lactose-sensitive LSBP^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

HaCaT
Concentration:

3.2, 12.5, 50 nM
Incubation Time:

24 h
Result:

Inhibited TNF-α-induced phosphorylation of NF-κB p65 at ser536 in a dose-dependent manner.
Had no effect on total NF-κB p65 expression.\nDownregulated TNF-α-induced IL-17A and IL-33 protein expression in a dose-dependent manner.

Cell Viability Assay^[1]

Cell Line:

HaCaT
Concentration:

50, 100, 200 μM
Incubation Time:

up to 6 days
Result:

Showed no obvious cytotoxicity in HaCaT cells treated at concentrations up to 200 μM over the 6-day incubation period.
Maintained cell viability comparable to DMSO-treated controls.

Cell Proliferation Assay^[2]

Cell Line:

human pancreatic ductal adenocarcinoma (PDAC) Suit2-007 cells, rat PDAC ASML cells
Concentration:

30, 40, 50, 60, 80, 100 μg/mL
Incubation Time:

48 h
Result:

Inhibited proliferation of Suit2-007 cells with an IC₅₀ value of 50 μg/mL.
Inhibited proliferation of ASML cells with an IC₅₀ value of 54 μg/mL.

RT-PCR^[3]

Cell Line:

human hepatoma Hep3B cells
Concentration:

20 μg/mL
Incubation Time:

30 min
Result:

Up-regulated TNFR I gene expression to the highest extent among the tested alkaloids, resulting in a TNFR II/I expression ratio of 0.95 (compared to a control ratio of 1.37).

In Vivo

Khasianine (0.1-25 μg/g; topical; 3 times daily; 4 days) potently ameliorates IMQ-induced psoriasis-like skin inflammation in mice by reducing immune cell infiltration and suppressing the TNF-α/NF-κB axis, along with downstream IL-17A and IL-33 expression^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (8 to 10 weeks of age; n=5 per treatment group; imiquimod-induced psoriasis-like skin inflammation)^[1]
Dosage:

0.1 μg/g, 1 μg/g, 5 μg/g, 25 μg/g; 5 μg/g (most effective)
Administration:

topical; 3 times daily; 4 days
Result:

Reduced clinical features of psoriasis-like inflammation, including scales, epidermal thickness, and immune cell infiltration.
Significantly reduced CD4+ T helper cells and macrophages in skin lesions.
Markedly decreased TNF-α-positive cells, total NF-κB p65-positive cells, phosphorylated NF-κB p65 (ser536)-positive cells, IL-17A-positive cells, and IL-33-positive cells in both epidermis and dermis.

Chemical Information

CAS No. 32449-98-2
Appearance Solid
Masse moléculaire 721.92
Formule C₃₉H₆₃NO₁₁
Color White to off-white
SMILES

C[C@@H]1[C@@]2(CC[C@@H](C)CN2)O[C@](C[C@@]3([H])[C@@](CC=C4[C@@]5(CC[C@H](O[C@]([C@@H]([C@@H](O)[C@@H]6O[C@@](O[C@@H](C)[C@H](O)[C@H]7O)([H])[C@@H]7O)O)([H])O[C@@H]6CO)C4)C)([H])[C@]5([H])CC8)([H])[C@@]1([H])[C@]38C
Structure Classification
- Alkaloids
- Piperidine Alkaloids
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (3)

All

Sort by:

Journal Impact Factor

Phytomedicine

Total alkaloids of Fritillaria unibracteata var. wabuensis bulbus ameliorate chronic asthma via the TRPV1/Ca2+/NFAT pathway. [Abstract]

2023 Sep:118:154946. PMID: 37421766
J Ethnopharmacol

Khasianine ameliorates psoriasis-like skin inflammation and represses TNF-α/NF-κB axis mediated transactivation of IL-17A and IL-33 in keratinocytes. [Abstract]

2022 Jun 28:292:115124. PMID: 35183690
Molecules

Metabolite Profiling and Anti-Inflammatory Activities of Fritillaria cirrhosa D. Don Bulbs Derived from Tissue Culture. [Abstract]

2025 Jan 31;30(3):623. PMID: 39942727

Solvant et solubilité

In Vitro:

DMSO : 50 mg/mL (69.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.3852 mL

6.9260 mL

13.8520 mL

5 mM

0.2770 mL

1.3852 mL

2.7704 mL

10 mM

0.1385 mL

0.6926 mL

1.3852 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.46 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.46 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.46 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (286 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Yang Y, et al. Khasianine ameliorates psoriasis-like skin inflammation and represses TNF-α/NF-κB axis mediated transactivation of IL-17A and IL-33 in keratinocytes. Journal of ethnopharmacology. 2022 Jun 28;292:115124. [Content Brief]

[2]. Sagini MN, et al. Khasianine Affects the Expression of Sugar-Sensitive Proteins in Pancreatic Cancer Cells, Which Are Altered in Data from the Rat Model and Patients. ACS pharmacology & translational science. 2023 May 12;6(5):727-737. [Content Brief]

[3]. Chang LC, et al. The rhamnose moiety of solamargine plays a crucial role in triggering cell death by apoptosis. Biochemical and biophysical research communications. 1998 Jan 06;242(1):21-5. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.3852 mL	6.9260 mL	13.8520 mL	34.6299 mL
	5 mM	0.2770 mL	1.3852 mL	2.7704 mL	6.9260 mL
	10 mM	0.1385 mL	0.6926 mL	1.3852 mL	3.4630 mL
	15 mM	0.0923 mL	0.4617 mL	0.9235 mL	2.3087 mL
	20 mM	0.0693 mL	0.3463 mL	0.6926 mL	1.7315 mL
	25 mM	0.0554 mL	0.2770 mL	0.5541 mL	1.3852 mL
	30 mM	0.0462 mL	0.2309 mL	0.4617 mL	1.1543 mL
	40 mM	0.0346 mL	0.1731 mL	0.3463 mL	0.8657 mL
	50 mM	0.0277 mL	0.1385 mL	0.2770 mL	0.6926 mL
	60 mM	0.0231 mL	0.1154 mL	0.2309 mL	0.5772 mL

Keywords

Khasianine

3 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Khasianine

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

TGF-beta/Smad Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Traditional Chinese Medicine Active Compound Library

Alkaloids Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Extracellular Vesicles (EVs) Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Khasianine

Voir tous les produits spécifiques à Isoform TNF Receptor

Voir tous les produits spécifiques à Isoform NF-κB

Voir tous les produits spécifiques à Isoform ROCK

Activité biologique

Chemical Information

Publications (3)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Khasianine Related Classifications

HY-N2322 Related Classifications